Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer

Major Program
Cancer Prevention Clinical Trials Network
Research Group
Breast and Gynecologic Cancer
National Cancer Institute (NCI)
Recruiting ID
For more information, see NCT04576104
This phase II trial studies the effect of megestrol acetate alone or in combination with metformin in preventing the progression of uterine pre-cancer (endometrial intraepithelial neoplasia) to endometrial cancer. Megestrol acetate is a drug used to block estrogen and suppress the effects of estrogen and androgens. It is the current non-surgical treatment of endometrial intraepithelial neoplasia. Metformin is a drug that has been found to have anti-cancer properties. Giving metformin and megestrol acetate together may decrease the growth of endometrial intraepithelial neoplasia in the uterus better than megestrol alone.
Biopsy, Extended Release Metformin Hydrochloride, Megestrol Acetate, Questionnaire Administration
Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Carcinoma
Emma Barber, Bradley R. Corr, Leslie H. Clark, Angeles A. Secord, Kevin M. Elias, Britt K. Erickson

See list of participating sites